GW Pharmaceuticals Plc is advancing development of its cannabidiol, Epidiolex, for the treatment of childhood epilepsy using cash raised during a recent follow-on offering of its American Depositary Shares on the US Nasdaq market. ---Subscribe to MedNous to access this article--- Company News
